Loading...
XNAS
SYBX
Market cap12mUSD
Dec 05, Last price  
1.03USD
1D
-10.43%
1Q
-29.45%
Jan 2017
-99.46%
IPO
-99.86%
Name

Synlogic Inc

Chart & Performance

D1W1MN
XNAS:SYBX chart
P/E
—
P/S
1,506.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
43.29%
Rev. gr., 5y
-67.55%
Revenues
8k
-99.76%
0000444,0002,444,0002,520,0002,224,000545,0001,754,0001,180,0003,371,0008,000
Net income
-23m
L-59.22%
-3,658,000-6,436,000-15,834,000-24,983,000-26,268,000-40,377,000-48,435,000-48,671,000-56,537,000-58,118,000-64,875,000-57,282,000-23,359,000
CFO
-32m
L-38.66%
-4,520,000-6,496,000-13,970,000-21,135,000-24,805,000-31,055,000-42,470,000-75,468,000-39,553,000-52,198,000-56,888,000-51,614,000-31,658,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
URL
https://www.synlogictx.com/
IPO date
Sep 30, 2015
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT